Effect of Ribavirin on Murine Cytomegalovirus Infection

Overview

Journal Antimicrob Agents Chemother

Publisher American Society for Microbiology

Specialty Pharmacology

Date 1976 Nov 1

PMID 188383

Citations 4

Authors

J N Dowling

B POSTIC

L O Guevarra

Affiliations

Soon will be listed here.

Abstract

Ribavirin (1-beta-d-ribofuranosyl-1,2,4-triazole-3-carboxamide), a new synthetic nucleoside, inhibited murine cytomegalovirus in cell culture. This was shown by the inhibition of viral cytopathic effect and plaque formation, as well as reduction in the yield of virus. Despite this in vitro antiviral effect, ribavirin did not protect mice from mortality produced by a high inoculum of cytomegalovirus. When a lower inoculum was used to initiate a chronic infection, the administration of ribavirin for 9 days had no effect on the titer of cytomegalovirus in the salivary gland, kidney, liver, and spleen. Thus, ribavirin was ineffective in the treatment of both acute and chronic murine cytomegalovirus infections.

Citing Articles

Toxicologic effects of ribavirin in cats.

Weiss R, Cox N, Boudreaux M J Vet Pharmacol Ther. 1993; 16(3):301-16.

PMID: 8230401 PMC: 7167023. DOI: 10.1111/j.1365-2885.1993.tb00177.x.

Effects of ribavirin on the development of the Friend leukemia.

Opitz U, Seidel H, STREISSLE G J Cancer Res Clin Oncol. 1980; 98(1):41-50.

PMID: 7451552 DOI: 10.1007/BF00413175.

Ribavirin and inosiplex: a review of their present status in viral diseases.

Chang T, Heel R Drugs. 1981; 22(2):111-28.

PMID: 6167418 DOI: 10.2165/00003495-198122020-00002.

Ribavirin: a clinical overview.

Fernandez H, Banks G, Smith R Eur J Epidemiol. 1986; 2(1):1-14.

PMID: 3021519 DOI: 10.1007/BF00152711.

References

Wu B, Dowling J, Armstrong J, Ho M . Enhancement of mouse cytomegalovirus infection during host-versus-graft reaction. Science. 1975; 190(4209):56-8. DOI: 10.1126/science.170676. View

RYTEL M, Kauffman H . Clinical efficacy of adenine arabinoside in therapy of cytomegalovirus infections in renal allograft recipients. J Infect Dis. 1976; 133(2):202-5. DOI: 10.1093/infdis/133.2.202. View

Kelsey D, Kern E, Overall Jr J, Glasgow L . Effect of cytosine arabinoside and 5-iodo-2'-deoxyuridine on a cytomegalovirus infection in newborn mice. Antimicrob Agents Chemother. 1976; 9(3):458-64. PMC: 429552. DOI: 10.1128/AAC.9.3.458. View

Streeter D, Witkowski J, Khare G, Sidwell R, Bauer R, ROBINS R . Mechanism of action of 1- -D-ribofuranosyl-1,2,4-triazole-3-carboxamide (Virazole), a new broad-spectrum antiviral agent. Proc Natl Acad Sci U S A. 1973; 70(4):1174-8. PMC: 433451. DOI: 10.1073/pnas.70.4.1174. View

Huffman J, Sidwell R, Khare G, Witkowski J, Allen L, ROBINS R . In vitro effect of 1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide (virazole, ICN 1229) on deoxyribonucleic acid and ribonucleic acid viruses. Antimicrob Agents Chemother. 1973; 3(2):235-41. PMC: 444393. DOI: 10.1128/AAC.3.2.235. View

Armstrong J . Semi-micro, dye-binding assay for rabbit interferon. Appl Microbiol. 1971; 21(4):723-5. PMC: 377263. DOI: 10.1128/am.21.4.723-725.1971. View

WELLER T . The cytomegaloviruses: ubiquitous agents with protean clinical manifestations. I. N Engl J Med. 1971; 285(4):203-14. DOI: 10.1056/NEJM197107222850406. View

KRAYBILL E, Sever J, Avery G, MOVASSAGHI N . Experimental use of cytosine arabinoside in congenital cytomegalovirus infection. J Pediatr. 1972; 80(3):485-7. DOI: 10.1016/s0022-3476(72)80514-6. View

McCracken Jr G, Luby J . Cytosine arabinoside in the treatment of congenital cytomegalic inclusion disease. J Pediatr. 1972; 80(3):488-93. DOI: 10.1016/s0022-3476(72)80515-8. View

10.

Sidwell R, Huffman J, Khare G, Allen L, Witkowski J, ROBINS R . Broad-spectrum antiviral activity of Virazole: 1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide. Science. 1972; 177(4050):705-6. DOI: 10.1126/science.177.4050.705. View

11.

Witkowski J, ROBINS R, Sidwell R, Simon L . Design, synthesis, and broad spectrum antiviral activity of 1- -D-ribofuranosyl-1,2,4-triazole-3-carboxamide and related nucleosides. J Med Chem. 1972; 15(11):1150-4. DOI: 10.1021/jm00281a014. View

12.

Stevens D, Jordan G, Waddell T, Merigan T . Adverse effect of cytosine arabinoside on disseminated zoster in a controlled trial. N Engl J Med. 1973; 289(17):873-8. DOI: 10.1056/NEJM197310252891701. View

13.

Fiala M, Chow A, Miyasaki K, Guze L . Susceptibility of herpesviruses to three nucleoside analogues and their combinations and enhancement of the antiviral effect of acid pH. J Infect Dis. 1974; 129(1):82-5. DOI: 10.1093/infdis/129.1.82. View

14.

Chien L, Cannon N, Whitley R, Diethelm A, Dismukes W, Scott C . Effect of adenine arabinoside on cytomegalovirus infections. J Infect Dis. 1974; 130(1):32-9. DOI: 10.1093/infdis/130.1.32. View

15.

Sidwell R, Allen L, Khare G, Huffman J, Witkowski J, Simon L . Effect of 1-beta-D-ribofuranosyl1-1,2,4-triazole-3-carboxamide (virazole, ICN 1229) on herpes and vaccinia keratitis and encephalitis in laboratory animals. Antimicrob Agents Chemother. 1973; 3(2):242-6. PMC: 444394. DOI: 10.1128/AAC.3.2.242. View

16.

Khare G, Sidwell R, Witkowski J, Simon L, ROBINS R . Suppression by 1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide (virazole, ICN 1229) of influenza virus-induced infections in mice. Antimicrob Agents Chemother. 1973; 3(4):517-22. PMC: 444445. DOI: 10.1128/AAC.3.4.517. View

17.

Mannini A, MEDEARIS Jr D . Mouse salivary gland virus infections. Am J Hyg. 1961; 73:329-43. DOI: 10.1093/oxfordjournals.aje.a120192. View

18.

MEDEARIS Jr D . MOUSE CYTOMEGALOVIRUS INFECTION. II. OBSERVATIONS DURING PROLONGED INFECTIONS. Am J Hyg. 1964; 80:103-12. View

19.

Osborn J, Walker D . Virulence and attenuation of murine cytomegalovirus. Infect Immun. 1971; 3(2):228-36. PMC: 416136. DOI: 10.1128/iai.3.2.228-236.1971. View